Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.36 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14542432 | 0.80 | — | — | |
| SCHEMBL18071087 | 0.79 | P2RX7 (0.31) | — | |
| SCHEMBL12436875 | 0.77 | GABRA5 (0.42) | KDM4EMAPTCYP1A2ALDH1A1GABRA1 | |
| SCHEMBL907575 | 0.76 | SMN1; SMN2 (0.43) | MAPTCYP1A2ALDH1A1CYP3A4TSHR | |
| SCHEMBL8128943 | 0.75 | — | — | |
| SCHEMBL5252856 | 0.75 | — | — | |
| SCHEMBL9564742 | 0.75 | THRA (0.36) | KDM4EMAPTCYP1A2PTGDR2PTGS1 | |
| SCHEMBL31688749 | 0.74 | SLC7A5 (0.44) | KDM4EMAPTALDH1A1CYP3A4TSHR | |
| SCHEMBL1404490 | 0.73 | KDM4E (0.37) | KDM4EMAPTCYP1A2ALDH1A1GABRA1 | |
| SCHEMBL27845043 | 0.73 | AGBL2 (0.41) | KDM4EMAPTCYP1A2ALDH1A1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1920073-A2 | METHOD OF SIMULTANEOUSLY VISUALIZING MULTIPLE BIOLOGICAL TARGETS | Dako Denmark A/S (DK) | 2008-05-14 | — | — | EP | claimed |
| WO-2007031874-A2 | METHOD OF SIMULTANEOUSLY VISUALIZING MULTIPLE BIOLOGICAL TARGETS | DAKO DENMARK A/S (US) | 2007-03-22 | — | — | WO | claimed |
| US-20040116453-A1 | Synthesis and methods of use pyrimidine analogues and derivatives | SPECTRUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | claimed |
| EP-1334103-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | claimed |
| EP-1334104-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | claimed |
| US-20030055249-A1 | Synthesis and methods of use of pyrimidine analogues and derivatives | NEOTHERAPEUTICS, INC. | 2003-03-20 | — | — | US | claimed |
| WO-2003007963-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | NEOTHERAPEUTICS, INC. (US) | 2003-01-30 | — | — | WO | claimed |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | NEOTHERAPEUTICS, INC. | 2002-09-12 | — | — | US | claimed |
| WO-2002058736-A2 | USE OF 9-SUBSTITUTED PURINE ANALOGUES AND OTHER MOLECULES TO STIMULATE NEUROGENESIS | NEOTHERAPETICS, INC. (US) | 2002-08-01 | — | — | WO | claimed |
| US-20020091133-A1 | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis | EVE M. TAYLOR | 2002-07-11 | — | — | US | claimed |
| US-20020061899-A1 | Methods for treatment of drug-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020055506-A1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | claimed |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | NEO THERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | NEOTHERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002004449-A2 | METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004450-A2 | METHODS FOR PREVENTION OF ACCUMULATION OF AMYLOID BETA PEPTIDE IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004452-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004451-A2 | METHODS FOR STIMULATION OF SYNTHESIS OF SYNAPTOPHYSIN IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004448-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| US-10036066-B2 | In situ hybridization detection method | DAKO DENMARK A/S (DK) | 2018-07-31 | — | — | US | disclosed |
| US-10036066-B2 | In situ hybridization detection method | DAKO DENMARK A/S (DK) | 2018-07-31 | — | — | US | disclosed |
| US-9598720-B2 | Monomeric and polymeric linkers useful for conjugating biological molecules and other substances | DAKO DENMARK A/S (DK) | 2017-03-21 | — | — | US | disclosed |
| US-9598720-B2 | Monomeric and polymeric linkers useful for conjugating biological molecules and other substances | DAKO DENMARK A/S (DK) | 2017-03-21 | — | — | US | disclosed |
| US-9598720-B2 | Monomeric and polymeric linkers useful for conjugating biological molecules and other substances | DAKO DENMARK A/S (DK) | 2017-03-21 | — | — | US | disclosed |
| US-20160273035-A1 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK A/S (DK) | 2016-09-22 | — | — | US | disclosed |
| US-20160273035-A1 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK A/S (DK) | 2016-09-22 | — | — | US | disclosed |
| US-20160273035-A1 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK A/S (DK) | 2016-09-22 | — | — | US | disclosed |
| EP-1919930-B1 | NEW NUCLEIC ACID BASE PAIRS | DAKO DENMARK AS (DK) | 2016-09-14 | — | — | EP | disclosed |
| US-9340824-B2 | Immunohistochemistry detection method | DAKO DENMARK A/S (DK) | 2016-05-17 | — | — | US | disclosed |
| US-9340824-B2 | Immunohistochemistry detection method | DAKO DENMARK A/S (DK) | 2016-05-17 | — | — | US | disclosed |
| US-9340824-B2 | Immunohistochemistry detection method | DAKO DENMARK A/S (DK) | 2016-05-17 | — | — | US | disclosed |
| US-9017992-B2 | In situ hybridization detection method | DAKO DENMARK A/S (DK) | 2015-04-28 | — | — | US | disclosed |
| US-9017992-B2 | In situ hybridization detection method | DAKO DENMARK A/S (DK) | 2015-04-28 | — | — | US | disclosed |
| US-9017992-B2 | In situ hybridization detection method | DAKO DENMARK A/S (DK) | 2015-04-28 | — | — | US | disclosed |
| EP-1910575-B1 | IMMUNOHISTOCHEMISTRY DETECTION METHOD | DAKO DENMARK AS (DK) | 2014-12-10 | — | — | EP | disclosed |
| EP-1910575-B1 | IMMUNOHISTOCHEMISTRY DETECTION METHOD | DAKO DENMARK AS (DK) | 2014-12-10 | — | — | EP | disclosed |
| US-20140315204-A1 | Immunohistochemistry Detection Method | DAKO DENMARK A/S (DK) | 2014-10-23 | — | — | US | disclosed |
| US-20140315204-A1 | Immunohistochemistry Detection Method | DAKO DENMARK A/S (DK) | 2014-10-23 | — | — | US | disclosed |
| US-20140315204-A1 | Immunohistochemistry Detection Method | DAKO DENMARK A/S (DK) | 2014-10-23 | — | — | US | disclosed |
| US-8741566-B2 | Immunohistochemistry and in situ hybridization detection method | DAKO DENMARK A/S (DK) | 2014-06-03 | — | — | US | disclosed |
| US-8741566-B2 | Immunohistochemistry and in situ hybridization detection method | DAKO DENMARK A/S (DK) | 2014-06-03 | — | — | US | disclosed |
| US-8741566-B2 | Immunohistochemistry and in situ hybridization detection method | DAKO DENMARK A/S (DK) | 2014-06-03 | — | — | US | disclosed |
| US-20140080145-A1 | Monomeric and Polymeric Linkers Useful For Conjugating Biological Molecules and Other Substances | DAKO DENMARK A/S (DK) | 2014-03-20 | — | — | US | disclosed |
| US-20140080145-A1 | Monomeric and Polymeric Linkers Useful For Conjugating Biological Molecules and Other Substances | DAKO DENMARK A/S (DK) | 2014-03-20 | — | — | US | disclosed |
| US-20140080145-A1 | Monomeric and Polymeric Linkers Useful For Conjugating Biological Molecules and Other Substances | DAKO DENMARK A/S (DK) | 2014-03-20 | — | — | US | disclosed |
| US-8653260-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653260-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653260-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8546309-B2 | Monomeric and polymeric linkers useful for conjugating biological molecules and other substances | DAKO DENMARK A/S (DK) | 2013-10-01 | — | — | US | disclosed |
| US-8546309-B2 | Monomeric and polymeric linkers useful for conjugating biological molecules and other substances | DAKO DENMARK A/S (DK) | 2013-10-01 | — | — | US | disclosed |
| US-8546309-B2 | Monomeric and polymeric linkers useful for conjugating biological molecules and other substances | DAKO DENMARK A/S (DK) | 2013-10-01 | — | — | US | disclosed |
| US-8501786-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501786-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501786-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8481697-B2 | Nucleic acid base pairs | DAKO DENMARK A/S (DK) | 2013-07-09 | — | — | US | disclosed |
| US-8481697-B2 | Nucleic acid base pairs | DAKO DENMARK A/S (DK) | 2013-07-09 | — | — | US | disclosed |
| US-8481697-B2 | Nucleic acid base pairs | DAKO DENMARK A/S (DK) | 2013-07-09 | — | — | US | disclosed |
| US-8399480-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399480-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399480-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2274296-B1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2274296-B1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2012-10-11 | — | — | US | disclosed |
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2012-10-11 | — | — | US | disclosed |
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2012-10-11 | — | — | US | disclosed |
| US-8247415-B2 | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247415-B2 | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2276756-B9 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2276756-B9 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2012010862-A3 | IMPROVED COMBUSTIBLE COMPOSITION | RECKITT BENCKISER SOUTH AFRICA (PTY) LIMITED (ZA) | 2012-05-10 | — | — | WO | disclosed |
| EP-2276756-B1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2011-11-30 | — | — | EP | disclosed |
| EP-2276756-B1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110177500-A1 | IMMUNOHISTOCHEMISTRY DETECTION METHOD | DAKO DENMARK AS (DK) | 2011-07-21 | — | — | US | disclosed |
| US-20110177500-A1 | IMMUNOHISTOCHEMISTRY DETECTION METHOD | DAKO DENMARK AS (DK) | 2011-07-21 | — | — | US | disclosed |
| US-20110177500-A1 | IMMUNOHISTOCHEMISTRY DETECTION METHOD | DAKO DENMARK AS (DK) | 2011-07-21 | — | — | US | disclosed |
| EP-1907592-B1 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | DAKO DENMARK AS (DK) | 2011-03-09 | — | — | EP | disclosed |
| EP-1907592-B1 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | DAKO DENMARK AS (DK) | 2011-03-09 | — | — | EP | disclosed |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2011-02-03 | — | — | US | disclosed |
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2011-02-03 | — | — | US | disclosed |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2011-02-03 | — | — | US | disclosed |
| EP-2276756-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2274296-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20100221705-A1 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK APS (DK) | 2010-09-02 | — | — | US | disclosed |
| US-20100221705-A1 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK APS (DK) | 2010-09-02 | — | — | US | disclosed |
| US-20100221705-A1 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK APS (DK) | 2010-09-02 | — | — | US | disclosed |
| US-20100120054-A1 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | DAKO DENMARK APS (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100120054-A1 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | DAKO DENMARK APS (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100120054-A1 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | DAKO DENMARK APS (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100105030-A1 | NUCLEIC ACID BASE PAIRS | DAKO DENMARK A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| US-20100105030-A1 | NUCLEIC ACID BASE PAIRS | DAKO DENMARK A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| US-20100105030-A1 | NUCLEIC ACID BASE PAIRS | DAKO DENMARK A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| US-20100105145-A1 | METHOD OF SIMULTANEOUSLY VISUALIZING MULTIPLE BIOLOGICAL TARGETS | DAKO DENMARK A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| US-20100105145-A1 | METHOD OF SIMULTANEOUSLY VISUALIZING MULTIPLE BIOLOGICAL TARGETS | DAKO DENMARK A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| US-20100105145-A1 | METHOD OF SIMULTANEOUSLY VISUALIZING MULTIPLE BIOLOGICAL TARGETS | DAKO DENMARK A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| WO-2009124166-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009124166-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009123870-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2009-10-08 | — | — | US | disclosed |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2009-10-08 | — | — | US | disclosed |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2009-10-08 | — | — | US | disclosed |
| WO-2009124167-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| EP-1919930-A2 | NEW NUCLEIC ACID BASE PAIRS | Dako Denmark A/S (DK) | 2008-05-14 | — | — | EP | disclosed |
| EP-1920072-A2 | IN SITU HYBRIDIZATION DETECTION METHOD | Dako Denmark A/S (DK) | 2008-05-14 | — | — | EP | disclosed |
| EP-1910575-A2 | IMMUNOHISTOCHEMISTRY DETECTION METHOD | Dako Denmark A/S (DK) | 2008-04-16 | — | — | EP | disclosed |
| EP-1907592-A2 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | Dako Denmark A/S (DK) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007031874-A9 | METHOD OF SIMULTANEOUSLY VISUALIZING MULTIPLE BIOLOGICAL TARGETS | DAKO DENMARK AS (DK) | 2007-05-31 | — | — | WO | disclosed |
| EP-1790344-A2 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | Spectrum Pharmaceuticals, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007045998-A2 | NEW NUCLEIC ACID BASE PAIRS | DAKO DENMARK A/S (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007031874-A2 | METHOD OF SIMULTANEOUSLY VISUALIZING MULTIPLE BIOLOGICAL TARGETS | DAKO DENMARK A/S (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007026252-A2 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK A/S (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007026252-A2 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK A/S (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007023390-A2 | IMMUNOHISTOCHEMISTRY DETECTION METHOD | DAKO DENMARK A/S (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023390-A2 | IMMUNOHISTOCHEMISTRY DETECTION METHOD | DAKO DENMARK A/S (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007015168-A2 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | DAKO DENMARK A/S (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015168-A2 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | DAKO DENMARK A/S (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20040116453-A1 | Synthesis and methods of use pyrimidine analogues and derivatives | SPECTRUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6630490-B2 | Purine derivative or analogue | NEOTHERAPEUTICS, INC. | 2003-10-07 | — | — | US | disclosed |
| US-6630478-B2 | Administering to patient with drug-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue | NEOTHERAPEUTICS, INC. | 2003-10-07 | — | — | US | disclosed |
| EP-1334103-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1334104-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20030055249-A1 | Synthesis and methods of use of pyrimidine analogues and derivatives | NEOTHERAPEUTICS, INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2003007963-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | NEOTHERAPEUTICS, INC. (US) | 2003-01-30 | — | — | WO | disclosed |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | NEOTHERAPEUTICS, INC. | 2002-09-12 | — | — | US | disclosed |
| WO-2002058736-A2 | USE OF 9-SUBSTITUTED PURINE ANALOGUES AND OTHER MOLECULES TO STIMULATE NEUROGENESIS | NEOTHERAPETICS, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| US-20020091133-A1 | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis | EVE M. TAYLOR | 2002-07-11 | — | — | US | disclosed |
| US-20020061899-A1 | Methods for treatment of drug-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| US-20020055506-A1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | disclosed |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | NEO THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | NEOTHERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002004449-A2 | METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004449-A2 | METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004450-A2 | METHODS FOR PREVENTION OF ACCUMULATION OF AMYLOID BETA PEPTIDE IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004452-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004451-A2 | METHODS FOR STIMULATION OF SYNTHESIS OF SYNAPTOPHYSIN IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004448-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061899-A1 | Methods for treatment of drug-induced peripheral neuropathy and related conditions | TYMP, TYMS, NGF | KDM4E 4248/4885MAPT 1343/4885CYP1A2 3535/4885 |
| US-20020055506-A1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | NGF, NUDT1, HPRT1 | KDM4E 4502/4885MAPT 587/4885CYP1A2 3918/4885 |
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | KDM4E 1791/4885MAPT 3296/4885CYP1A2 152/4885 |
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | KDM4E 1791/4885MAPT 3296/4885CYP1A2 152/4885 |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | KDM4E 1791/4885MAPT 3296/4885CYP1A2 152/4885 |
| US-20140080145-A1 | Monomeric and Polymeric Linkers Useful For Conjugating Biological Molecules and Other Substances | PCNA, DCLRE1A, TK1 | KDM4E 4606/4885MAPT 1037/4885CYP1A2 4786/4885 |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | GAP43, BDNF, APP | KDM4E 3620/4885MAPT 213/4885CYP1A2 2773/4885 |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | SLC29A1, ABCB1, NUDT1 | KDM4E 3123/4885MAPT 3440/4885CYP1A2 807/4885 |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | KDM4E 1825/4885MAPT 3311/4885CYP1A2 190/4885 |
| US-20020091133-A1 | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis | DCX, MKI67, TK2 | KDM4E 837/4885MAPT 4186/4885CYP1A2 1075/4885 |
| US-20030055249-A1 | Synthesis and methods of use of pyrimidine analogues and derivatives | ATIC, SLC29A1, ABCG2 | KDM4E 2605/4885MAPT 2567/4885CYP1A2 512/4885 |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | APP, BACE1, SARNP | KDM4E 4596/4885MAPT 90/4885CYP1A2 2381/4885 |
| US-20100105030-A1 | NUCLEIC ACID BASE PAIRS | NSUN3, NCL, NSUN2 | KDM4E 4822/4885MAPT 2261/4885CYP1A2 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.